Treatment of Herpes Labialis
For episodic treatment of herpes labialis, initiate oral antiviral therapy with either valaciclovir 2g twice daily for 1 day or famciclovir 1500mg as a single dose, starting at the first sign of prodrome or within 48 hours of lesion onset. 1
Episodic Treatment Approach
First-Line: Systemic Oral Antivirals
Systemic oral antivirals are superior to topical formulations and should be your primary choice 2. The evidence strongly supports short-course, high-dose regimens:
Valaciclovir:
- 2g twice daily for 1 day (most convenient regimen)
- Alternative: 2g twice daily on Day 1, then 1g twice daily on Day 2
- Reduces median episode duration to 4.0-5.0 days vs 5.0 days with placebo (p <0.001) 1
- Meta-analysis shows valaciclovir is more effective than aciclovir in reducing healing time and pain resolution 3
Famciclovir:
- 1500mg single dose for 1 day
- Significantly reduces time to return to normal skin (2.9 days vs 4.5 days with placebo, p <0.001) 1
- Alternative: 750mg twice daily for 1 day
Aciclovir (if valaciclovir/famciclovir unavailable):
- 400mg five times daily for 5 days (less convenient dosing)
- 800mg twice daily for 3-7 days
- Reduces pain duration (2.5 vs 3.9 days with placebo, p=0.02) 1
Critical Timing Consideration
Treatment must begin during the prodromal stage or within 48 hours of lesion onset to achieve optimal results 2. This is why pharmacy-controlled access (rather than prescription-only) is recommended—it eliminates delays in treatment initiation 1.
Second-Line: Topical Antivirals
Use topical agents only when oral therapy is contraindicated or unavailable:
- 5% aciclovir cream (apply 5 times daily)
- 1% penciclovir cream (apply every 2 hours while awake)
- Aciclovir 5% + hydrocortisone 1% (Xerese) - the anti-inflammatory component may enhance efficacy 4
Important caveat: Topical antivirals are not effective for preventing recurrent episodes 2. A 2020 study showed no significant difference in healing time between topical aciclovir and non-antiviral alternatives 5.
Chronic Suppressive Therapy
Consider daily suppressive therapy for patients with ≥6 episodes per year or severe recurrences 2:
- Valaciclovir 500mg once daily for 4 months or longer
- Extends time to recurrence (13.1 weeks vs 9.6 weeks with placebo, p=0.016) 1
- Results in 60% of patients remaining recurrence-free vs 38% with placebo 1
Alternative: Aciclovir 400mg twice daily for 4 months (53% fewer clinical recurrences, p=0.009) 1
Adjunctive Symptomatic Management
For mild symptoms or as adjunct to antivirals 6:
- Topical zinc sulfate/zinc oxide
- Systemic analgesics or topical lidocaine for pain relief
- Local anesthetics (lidocaine/prilocaine combinations) show both analgesic and antiviral properties 7
Comparative Efficacy Summary
Based on meta-analysis of 8,453 patients 3:
- Nucleoside antivirals reduce healing time of all lesions by 0.74 days (95% CI: -0.86, -0.62)
- Classic lesions heal 1.09 days faster (95% CI: -1.27, -0.92)
- Pain resolution occurs 0.38 days earlier (95% CI: -0.58, -0.18)
- Valaciclovir demonstrates superior efficacy compared to aciclovir in reducing healing time and pain
Common Pitfalls to Avoid
Delayed treatment initiation: Waiting for full lesion development significantly reduces antiviral efficacy. Educate patients to self-medicate at first prodromal symptoms 1.
Prescribing topical antivirals for prevention: These are ineffective for prophylaxis; only oral antivirals work for suppression 2.
Using 5-day aciclovir regimens when 1-day valaciclovir/famciclovir available: The shorter regimens offer equal or superior efficacy with better adherence 1.
Inadequate dosing frequency with aciclovir: The 5-times-daily regimen is necessary but often poorly adhered to; valaciclovir/famciclovir are preferable 2.
Safety Profile
All nucleoside antivirals demonstrate excellent safety profiles with minimal adverse events across studies 3, 5. Both systemic and topical formulations are well-tolerated and recommended 3.